Image of hero exercising

She is doing all she
can. Is GIP
the missing link?

GIP: An Incretin Hormone with Diverse Metabolic Roles

GIP is 1 of 2 hormones involved in the incretin effect1

Both GIP and GLP-1 are hormones secreted by the gut in response to nutrient load. They are responsible for the incretin effect, which enhances the secretion of insulin after a meal.1

GIP and GLP-1: similarities and differences

GIP has other functions as well. The latest research has shown that GIP may impact weight-related mechanisms, such as food intake and appetite.1-3 Additionally, several genetic association studies link GIP to the regulation of insulin, glucose, lipids, and body weight.4-7

Icon for Brain

Brain

GIP Activity

ArrowDown Reduced food intake*

GLP-1 Activity

ArrowDown Reduced food intake

ArrowUp Increased satiety

Icon for Subcutaneous White Adipose Tissue

Subcutaneous White Adipose Tissue

GIP Activity

ArrowUp Increased insulin sensitivity*

ArrowUp Increased lipid buffering capacity*

ArrowUp Increased storage capacity*

Icon for Pancreas

Pancreas

GIP Activity

ArrowUp Increased insulin

ArrowUp Increased glucagon

GLP-1 Activity

ArrowUp Increased insulin

ArrowDown Reduced glucagon

Icon for Stomach

Stomach

GLP-1 Activity

ArrowDown Reduced gastric emptying

*Derived from preclinical studies; Selected information derived from: Samms RJ, Coghlan MP, Sloop KW. How may GIP enhance the therapeutic efficacy of GLP-1? Trends Endocrinol Metab. 2020;31(6):416.

Icon for blood sugar

The incretin effect is diminished in T2D1

Over time, hyperglycemia is associated with nephropathy, retinopathy, and CV disease.8

WATCH THIS VIDEO TO LEARN MORE ABOUT THE ROLE OF GIP IN T2D

Image of hero exercising

Discover the significant role GIP
plays in regulating blood glucose.

CV=cardiovascular; GIP=glucose-dependent insulinotropic polypeptide; GLP-1=glucagon-like peptide-1; T2D=type 2 diabetes.

References

  1. Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol. 2016;4(6):525-536. doi:10.1016/S2213-8587(15)00482-9
  2. Nauck MA, Meier JJ. Incretin hormones: Their role in health and disease. Diabetes Obes Metab. 2018 Feb;20 Suppl 1:5-21. DeFronzo, R.A. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia 53, 1270-1287 (2010).
  3. Finan B, Müller TD, Clemmensen C, et al. Reappraisal of GIP pharmacology for metabolic diseases. Trends Mol Med. 2016;22(5):359-376. doi:10.1016/j.molmed.2016.03.005
  4. Saxena R, Hivert MF, Langenberg C, et al. Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet. 2010;42(2):142-148. doi:10.1038/ng.521
  5. Speliotes EK, Willer CH, Berndt SI, et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet. 2010;42(11):937-948. doi:10.1038/ng.686
  6. Karhunen V, Daghlas I, Zuber V, et al. Leveraging human genetic data to investigate the cardiometabolic effects of glucose-dependent insulinotropic polypeptide signalling. Diabetologia. Published online September 9, 2021. doi:10.1007/s00125-021-05564-7
  7. Bowker N, Hansford R, Burgess S, et al. Genetically predicted glucose-dependent insulinotropic polypeptide (GIP) levels and cardiovascular disease risk are driven by distinct causal variants in the GIPR region. Diabetes. 2021;70(11):2706-2719. doi:10.2337/db21-0103
  8. American Diabetes Association. Standards of medical care in diabetes-2021. Diabetes Care. 2021;44(suppl 1):S1-S232